SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (841)7/1/2004 9:30:21 AM
From: Icebrg  Read Replies (1) of 2240
 
Anti-anthrax mAb

Microbiology professor Ronald Taylor presented his research, thus far successful, in developing an antidote to anthrax. Taylor's antidote not only prevents infection after exposure, but also can actually treat infection. His work is partially funded by the Institute for Security Technology Studies, which receives funding from the federal government.

Taylor said he has developed an anthrax antibody that prevents fatality with an 80 to 90 percent success rate prior to exposure and a 60 percent success rate after infection in rabbits. During the anthrax mailing campaign that struck the U.S. government and news organizations in 2002, half of those exposed died despite the administration of antibodies. Taylor conducted his research in collaboration with the U.S. Army and the private biotech firm Medarex.

He said his antibody provides the best protection at the lowest doses, and is the only treatment that has been shown to actually reverse symptoms of the infection. Although Taylor said the cost of bringing the product to market, including testing on monkeys and humans to receive FDA approval, would be only $22 to $30 million, the National Institutes of Health has not yet approved the project for funding.

thedartmouth.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News